| scholarly article | Q13442814 |
| P2093 | author name string | P. S. Aisen | |
| C. R. Jack | |||
| R. A. Sperling | |||
| P2860 | cites work | Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 |
| Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | Q29614407 | ||
| Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease | Q33560183 | ||
| Amyloid imaging in mild cognitive impairment subtypes. | Q33689424 | ||
| Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup | Q33969633 | ||
| Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease | Q34247849 | ||
| Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease | Q34606557 | ||
| Cognition, reserve, and amyloid deposition in normal aging | Q34783920 | ||
| Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease | Q35029086 | ||
| Amyloid-β associated cortical thinning in clinically normal elderly | Q35053524 | ||
| An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease | Q36650399 | ||
| Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects | Q37181281 | ||
| Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease | Q37181302 | ||
| MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations | Q37273551 | ||
| A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system | Q37316153 | ||
| Amyloid deposition is associated with impaired default network function in older persons without dementia | Q37335603 | ||
| Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment | Q37415283 | ||
| 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study | Q37699953 | ||
| Amyloid-dependent and amyloid-independent stages of Alzheimer disease | Q37863977 | ||
| Resolving controversies on the path to Alzheimer's therapeutics | Q39709721 | ||
| Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults | Q40253365 | ||
| Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study | Q40349700 | ||
| Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging | Q43062420 | ||
| Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome | Q45007178 | ||
| CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. | Q45923691 | ||
| PET imaging of amyloid deposition in patients with mild cognitive impairment | Q48169392 | ||
| Abeta species removal after abeta42 immunization | Q48378187 | ||
| Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds | Q48388907 | ||
| Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. | Q48852013 | ||
| Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. | Q48893777 | ||
| Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. | Q48963534 | ||
| CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study | Q50413832 | ||
| Episodic memory decline predicts cortical amyloid status in community-dwelling older adults. | Q50994715 | ||
| Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. | Q51867713 | ||
| Biochemical markers in persons with preclinical familial Alzheimer disease. | Q53294586 | ||
| Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. | Q53419819 | ||
| P433 | issue | 111 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 111cm33 | |
| P577 | publication date | 2011-11-30 | |
| P1433 | published in | Science Translational Medicine | Q1573955 |
| P1476 | title | Testing the right target and right drug at the right stage | |
| P478 | volume | 3 |
| Q35864788 | A Peephole into the Brain: Neuropathological Features of Alzheimer's Disease Revealed by in vivo Two-Photon Imaging |
| Q47991497 | A Simple Tool to Reach Populations at Risk for Developing Dementia and Alzheimer's Disease |
| Q40101067 | A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers |
| Q33813921 | A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium |
| Q90079282 | A comparative study on the validations of three cognitive screening tests in identifying subtle cognitive decline |
| Q35049917 | A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease |
| Q28544423 | A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's disease |
| Q38378475 | A phase 3 trial of IV immunoglobulin for Alzheimer disease |
| Q35879102 | A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease |
| Q47650724 | APOE genotype and early β-amyloid accumulation in older adults without dementia |
| Q58121166 | Aberrant functional connectivity network in subjective memory complaint individuals relates to pathological biomarkers |
| Q37580147 | Abnormal organization of white matter networks in patients with subjective cognitive decline and mild cognitive impairment |
| Q36918859 | Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology |
| Q64244594 | Actual memory as a mediator of the amyloid-subjective cognitive decline relationship |
| Q60045502 | Advances in developing novel therapeutic strategies for Alzheimer's disease |
| Q38299414 | Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future |
| Q30458193 | Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria |
| Q33642389 | After disappointments, Alzheimer's researchers seek out new paths: biomarkers and combination therapies may lead to disease-modifying treatments, experts say. |
| Q24594531 | Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play |
| Q36574825 | Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies |
| Q47784298 | Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults |
| Q51760876 | Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies. |
| Q60313667 | Alzheimer's disease |
| Q89841160 | Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How |
| Q37363931 | Alzheimer's disease severity, objectively determined and measured |
| Q35858153 | Alzheimer’s disease: the new promise |
| Q36457001 | Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals |
| Q34332159 | Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study |
| Q38224958 | Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return? |
| Q37291586 | Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity |
| Q38887384 | An overview of circulating cell-free microRNAs as putative biomarkers in Alzheimer's and Parkinson's Diseases |
| Q37387826 | Are CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical Setting |
| Q40457164 | Are We Ready? The Construct of Subjective Cognitive Impairment and its Utilization in Clinical Practice: A Preliminary UK-Based Service Evaluation. |
| Q47206109 | Arterial-spin-labeling (ASL) perfusion MRI predicts cognitive function in elderly individuals: A 4-year longitudinal study. |
| Q41099743 | Associations between Homocysteine, Folic Acid, Vitamin B12 and Alzheimer's Disease: Insights from Meta-Analyses |
| Q90697479 | Astaxanthin Ameliorated Parvalbumin-Positive Neuron Deficits and Alzheimer's Disease-Related Pathological Progression in the Hippocampus of AppNL-G-F/NL-G-F Mice |
| Q39010379 | Attitudes toward Potential Participant Registries |
| Q42278977 | Attitudes toward clinical trials across the Alzheimer's disease spectrum |
| Q51745823 | Author response to comment on "drug discovery: turning the titanic". |
| Q38797428 | Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease |
| Q38416584 | Biochemical and neuroimaging studies in subjective cognitive decline: progress and perspectives. |
| Q37592824 | Biomarker modeling of Alzheimer's disease |
| Q38166669 | Biomarker modelling of early molecular changes in Alzheimer's disease |
| Q36612922 | Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough |
| Q38592041 | Biomarkers in Sporadic and Familial Alzheimer's Disease |
| Q92862699 | Brain Glucose Metabolism, Cognition, and Cardiorespiratory Fitness Following Exercise Training in Adults at Risk for Alzheimer's Disease |
| Q36841536 | Brain β-amyloid load approaches a plateau |
| Q36843004 | CAP--advancing the evaluation of preclinical Alzheimer disease treatments |
| Q36990425 | CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology |
| Q59049398 | CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design |
| Q28273817 | Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography |
| Q50199042 | Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. |
| Q82511885 | Challenges of Integrative Disease Modeling in Alzheimer's Disease |
| Q34303501 | Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention |
| Q38300738 | Charting a path toward combination therapy for Alzheimer's disease |
| Q37395823 | Choosing Alzheimer's disease prevention clinical trial populations |
| Q98735793 | Circulating Cell-Free Nucleic Acids as Epigenetic Biomarkers in Precision Medicine |
| Q61811517 | Circulating antioxidants and Alzheimer disease prevention: a Mendelian randomization study |
| Q37158033 | Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies |
| Q37044224 | Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease |
| Q40114382 | Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers |
| Q33563786 | Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance |
| Q36463140 | Cognitive/Clinical Endpoints for Pre-Dementia AD Trials |
| Q60512507 | Computational modeling and biomarker studies of pharmacological treatment of Alzheimer's disease (Review) |
| Q92615340 | Current Status of the Vietnam Era Twin Study of Aging (VETSA) |
| Q38778638 | Defeating Alzheimer's disease and other dementias: a priority for European science and society |
| Q38095360 | Developing therapeutic antibodies for neurodegenerative disease |
| Q34051576 | Development of a psychometrically equivalent short form of the Face-Name Associative Memory Exam for use along the early Alzheimer's disease trajectory |
| Q27012742 | Development of positron emission tomography β-amyloid plaque imaging agents |
| Q64059925 | Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers |
| Q28088506 | Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis |
| Q98726578 | Differences in cohort study data affect external validation of artificial intelligence models for predictive diagnostics of dementia - lessons for translation into clinical practice |
| Q64241548 | Different Modulation Effects of Tai Chi Chuan and Baduanjin on Resting State Functional Connectivity of the Default Mode Network in Older Adults |
| Q42252548 | Differential diagnosis of Alzheimer's disease using spectrochemical analysis of blood. |
| Q35977886 | Direct medical costs and source of cost differences across the spectrum of cognitive decline: a population-based study |
| Q50105066 | Disclosing genetic risk of Alzheimer's disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study. |
| Q36638757 | Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials |
| Q34498158 | Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa |
| Q39558338 | Discrepancies between fluid and crystallized ability in healthy adults: a behavioral marker of preclinical Alzheimer's disease. |
| Q38583222 | Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective. |
| Q34419108 | Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target? |
| Q37689963 | Dominantly Inherited Alzheimer Network: facilitating research and clinical trials |
| Q28247764 | Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model |
| Q38966308 | Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients. |
| Q34452239 | Enrichment and stratification for predementia Alzheimer disease clinical trials |
| Q37093415 | Familiarity-based memory as an early cognitive marker of preclinical and prodromal AD. |
| Q83231549 | Family history of Alzheimer's disease alters cognition and is modified by medical and genetic factors |
| Q35776386 | Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease |
| Q36934148 | Function and clinical meaningfulness of treatments for mild Alzheimer's disease |
| Q37170455 | Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues |
| Q99240702 | Hippocampal Resting-State Functional Connectivity Patterns are More Closely Associated with Severity of Subjective Memory Decline than Whole Hippocampal and Subfield Volumes |
| Q58697674 | How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture |
| Q37180765 | Identifying the Alteration Patterns of Brain Functional Connectivity in Progressive Mild Cognitive Impairment Patients: A Longitudinal Whole-Brain Voxel-Wise Degree Analysis. |
| Q50044294 | Imaging Alzheimer's disease pathophysiology with PET. |
| Q42653687 | Imaging Vascular Disease and Amyloid in the Aging Brain: Implications for Treatment |
| Q49026171 | Imaging biomarkers for amyloid: a new generation of probes and what lies ahead. |
| Q49957645 | Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. |
| Q26801629 | Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 |
| Q36330933 | Indicators of amyloid burden in a population-based study of cognitively normal elderly |
| Q61805640 | Integrated Cognitive Assessment: Speed and Accuracy of Visual Processing as a Reliable Proxy to Cognitive Performance |
| Q27438189 | Interictal spikes during sleep are an early defect in the Tg2576 mouse model of β-amyloid neuropathology |
| Q64932512 | Intranasal rifampicin for Alzheimer's disease prevention. |
| Q47141112 | Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease: Methodology and Baseline Sample Characteristics |
| Q53441656 | Lifelong management of amyloid-beta metabolism to prevent Alzheimer's disease. |
| Q35900301 | Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study |
| Q48116946 | MEG biomarker of Alzheimer's disease: Absence of a prefrontal generator during auditory sensory gating. |
| Q30660402 | Magnetic resonance spectroscopy in common dementias |
| Q44135893 | Mapping the road forward in Alzheimer's disease |
| Q99563527 | Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer's disease |
| Q53343625 | Measuring decline in prodromal AD: a pike to hike. |
| Q34260002 | Metal chaperones: a holistic approach to the treatment of Alzheimer's disease |
| Q37610213 | Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease |
| Q27026362 | Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments |
| Q34651135 | Molecular imaging of Alzheimer disease pathology |
| Q53338097 | Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. |
| Q36173392 | Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects |
| Q52589491 | NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. |
| Q36465116 | Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer's disease |
| Q58701472 | Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial |
| Q34204123 | Obstacles and opportunities in Alzheimer's clinical trial recruitment |
| Q28275093 | Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination |
| Q47141681 | Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5. |
| Q36082829 | Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker |
| Q34620989 | Our "energy-Ca(2+) signaling deficits" hypothesis and its explanatory potential for key features of Alzheimer's disease |
| Q35561896 | Participation in cognitively-stimulating activities is associated with brain structure and cognitive function in preclinical Alzheimer's disease. |
| Q53446494 | Passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed? |
| Q38344088 | Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies |
| Q52644591 | Patient Engagement: The Fundació ACE Framework for Improving Recruitment and Retention in Alzheimer's Disease Research. |
| Q43604874 | Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment |
| Q36553629 | Pharmacological lifespan extension of invertebrates |
| Q47682467 | Physical Activity in Preventing Alzheimer's Disease and Cognitive Decline: A Narrative Review |
| Q41690745 | Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals |
| Q37445069 | Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study |
| Q55480248 | Potential Utility of Retinal Imaging for Alzheimer’s Disease: A Review. |
| Q34014237 | Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials |
| Q36813484 | Preclinical Alzheimer disease-the challenges ahead |
| Q35977212 | Predictive testing for Alzheimer's disease: suicidal ideation in healthy participants |
| Q37415094 | Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study. |
| Q91882184 | Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework |
| Q35800785 | Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis |
| Q40059147 | Prevalence, Risk Factors, and Complaints Screening Tool Exploration of Subjective Cognitive Decline in a Large Cohort of the Chinese Population |
| Q39549596 | Preventing Alzheimer's disease |
| Q34652047 | Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment |
| Q38719665 | Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives |
| Q38554910 | Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions |
| Q38983318 | Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics |
| Q40142384 | Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study |
| Q37670673 | Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward |
| Q37626382 | Progress update: fluid and imaging biomarkers in Alzheimer's disease |
| Q37689697 | Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review |
| Q30606675 | Proton MRS in mild cognitive impairment |
| Q60934511 | Quantitative Electroencephalography Analyzed by Statistical Pattern Recognition as a Diagnostic and Prognostic Tool in Mild Cognitive Impairment: Results from a Nordic Multicenter Cohort Study |
| Q44968491 | RETRACTED: Elevation of brain magnesium prevents and reverses cognitive deficits and synaptic loss in Alzheimer's disease mouse model. |
| Q33617293 | Randomized controlled trials in mild cognitive impairment: Sources of variability |
| Q34372593 | Rates of decline in Alzheimer disease decrease with age. |
| Q36424806 | Recent Alzheimer's disease research highlights |
| Q99400826 | Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD) |
| Q50553660 | Reduced grid-cell-like representations in adults at genetic risk for Alzheimer's disease. |
| Q39613391 | Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study |
| Q34047125 | Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum |
| Q58103185 | Report: NIA workshop on translating genetic variants associated with longevity into drug targets |
| Q92608243 | Resting State Abnormalities of the Default Mode Network in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis |
| Q50525085 | Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers. |
| Q93046699 | Risk Factors and Neuropsychological Assessments of Subjective Cognitive Decline (plus) in Chinese Memory Clinic |
| Q36279869 | Role of genes linked to sporadic Alzheimer's disease risk in the production of β-amyloid peptides |
| Q34180267 | SIST-M-IR activities of daily living items that best discriminate clinically normal elderly from those with mild cognitive impairment |
| Q47134237 | Screening for Alzheimer's Disease: Cognitive Impairment in Self-Referred and Memory Clinic-Referred Patients |
| Q36415014 | Screening for mild cognitive impairment: If not now, when? |
| Q36934154 | Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score |
| Q33984761 | Sex modifies the APOE-related risk of developing Alzheimer disease |
| Q92794075 | Shifting equilibriums in Alzheimer's disease: the complex roles of microglia in neuroinflammation, neuronal survival and neurogenesis |
| Q34286140 | Should we disclose amyloid imaging results to cognitively normal individuals? |
| Q38871392 | Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? |
| Q92678345 | Spatial distributions of cholinergic impairment and neuronal hypometabolism differ in MCI due to AD |
| Q91635222 | Structural and Functional Hippocampal Changes in Subjective Cognitive Decline From the Community |
| Q34338974 | Structure-activity relationships for a series of compounds that inhibit aggregation of the Alzheimer's peptide, Aβ42 |
| Q37683684 | Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients. |
| Q36322792 | Subjective cognitive complaints and amyloid burden in cognitively normal older individuals |
| Q62830975 | Subthreshold Amyloid Predicts Tau Deposition in Aging |
| Q92553473 | Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid |
| Q28650529 | Template based rotation: a method for functional connectivity analysis with a priori templates |
| Q93018917 | The "rights" of precision drug development for Alzheimer's disease |
| Q33725775 | The A4 study: stopping AD before symptoms begin? |
| Q31147579 | The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement |
| Q36149767 | The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment |
| Q57299988 | The Combination of Functional and Structural MRI Is a Potential Screening Tool in Alzheimer's Disease |
| Q36165011 | The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations |
| Q36055855 | The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome |
| Q34849048 | The evolution of preclinical Alzheimer's disease: implications for prevention trials |
| Q41206882 | The impact of companion diagnostic device measurement performance on clinical validation of personalized medicine |
| Q47587926 | The impact of genetic counselors' use of facilitative strategies on cognitive and emotional processing of genetic risk disclosure for Alzheimer's disease |
| Q37063351 | The neuritic plaque facilitates pathological conversion of tau in an Alzheimer's disease mouse model |
| Q37251058 | The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study |
| Q34422469 | The preclinical Alzheimer cognitive composite: measuring amyloid-related decline |
| Q37998086 | The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update |
| Q30419992 | Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress |
| Q35418054 | Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument |
| Q38780625 | Trajectories of Depressive Symptoms Before Diagnosis of Dementia: A 28-Year Follow-up Study. |
| Q48303439 | Translational strategies in aging and age-related disease |
| Q26824702 | Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales |
| Q34157492 | Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease |
| Q37031161 | Uncoupling neuronal death and dysfunction in Drosophila models of neurodegenerative disease |
| Q30845482 | Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease |
| Q51766801 | Use of an Alzheimer's disease polygenic risk score to identify mild cognitive impairment in adults in their 50s. |
| Q37227059 | Using AD biomarker research results for clinical care: a survey of ADNI investigators |
| Q47096390 | Validation and diagnostic accuracy of predictive curves for age-associated longitudinal cognitive decline in older adults |
| Q58758799 | Visual Attention Performances and Related Cerebral Microstructural Integrity Among Subjects With Subjective Cognitive Decline and Mild Cognitive Impairment |
| Q37106748 | White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration |
| Q57911678 | fMRI in Neurodegenerative Diseases: From Scientific Insights to Clinical Applications |
Search more.